Abstract
Elderly individuals are susceptible to autoimmune bullous dermatoses (in particular, pemphigoid, epidermolysis bullosa acquisita and paraneoplastic pemphigus). Bullous dermatoses are associated with high morbidity and mortality. Bullous dermatoses result from autoimmune responses to one or more components of the basement membrane or desmosomes.
Pemphigoid results from autoimmunity to hemidesmosomal proteins present in the basement membrane of stratified squamous epithelia. Patients present with tense blisters in flexural areas of the skin. Mild or moderate bullous pemphigoid may be treated with potent topical corticosteroids while extensive disease usually requires systemic corticosteroids or systemic immunosuppressive agents such as azathioprine. Mucosal pemphigoid affects one or more mucous membranes that are lined by stratified squamous epithelia. The two most commonly involved sites are the eye and the oral cavity. Lesions frequently result in scar formation, which may cause blindness. Patients with severe disease or ocular involvement require aggressive therapy with corticosteroids and cyclophosphamide.
Epidermolysis bullosa acquisita results from autoimmunity to type VII collagen in the anchoring fibrils of the basement membrane area. Lesions may either arise on an inflammatory base or be non-inflammatory and result primarily from trauma. The inflammatory type of the disease is more responsive to therapy than the non-inflammatory type. Treatment options include corticosteroids, dapsone, cyclosporin, plasmapheresis and immunoglobulin G.
Paraneoplastic pemphigus results from autoimmunity to multiple antigens within the desmosomes. The disorder is associated with neoplasms, especially leukaemia and lymphoma. Patients present with severe stomatitis and polymorphous skin eruption. The mucosal and cutaneous involvement may respond to successful treatment of the underlying neoplasm or may require immunosuppressive therapy.
Similar content being viewed by others
References
Grove GL, Duncan S, Kligman AM. Effect of aging on the blistering of human skin with ammonium hydroxide. Br J Dermatol 1982; 107: 383–400
Montagna W, Carlisle K. Structural changes in aging human skin. J Invest Dermatol 1979; 73: 47–53
Dubey DP, Yunis EJ. Aging and nutritional effects on immune functions in humans. In: Stites DP, Terr AI, editors. Basic and clinical immunology. 7th ed. Norwalk (CT): Appleton and Lange, 1991: 190–3
Burgeson RE, Christiano AM. The dermal-epidermal junction. Curr Opin Cell Biol 1998; 9: 651–8
Roscoe JT, Diaz L, Sampaio SA, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985; 85: 538–41
Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189–96
Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869–77
Beutner EH, Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964; 117: 505–10
Rappersberger K, Roos N, Stanley JR. Immunomorphological and biochemical identification of the pemphigus foliaceus autoantigen within desmosomes. J Invest Dermatol 1992; 99: 323–30
Karpati S, Amagai M, Prussick R, et al. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol 1993; 122: 409–15
Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291–325
Eyre RW, Stanley JR. Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest 1988; 81: 807–12
Hu CH, Michel B, Schlitz JR. Epidermal acantholysis induced in vitro by pemphigus autoantibody. Am J Pathol 1978; 90: 345–51
Diaz LA, Giudice GJ. End of the century overview of skin blisters. Arch Dermatol 2000; 136: 106–12
Stanley JR. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 1989; 83: 1443–8
Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997; 100: 1256–63
Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP 180. J Clin Invest 1993; 92: 2480–8
Anhalt GJ, Nousari HC. Bullous diseases. In: Rakel RE, Bope EJ, editors. Conn’s Current Therapy. Philadelphia (PA): Saunders, 2003: 918–25
Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia: WB Saunders Company, 2001
Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001
Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 1986; 122: 670–4
Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51–5
Humbert P, Treffel P, Chapuis JF, et al. The tetracyclines in dermatology. J Am Acad Dermatol 1991; 25: 691–7
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747–55
Rook A, Wilkinson DS, Ebling FJG, editors. Textbook of dermatology. Oxford: Blackwell Scientific Publications, 1979: 1462–65
Bean SF. Bullous pemphigoid. In: Ahmed AR, editor. Clinics in dermatology. Philadelphia: JB Lippincott, 1987: 13–7
Marsden RA, McKee PH, Bhogal B, et al. A study of benign chronic bullous dermatosis of childhood and comparison with dermatitis herpetiformis and bullous pemphigoid occurring in childhood. Clin Exp Dermatol 1980; 5: 159–72
Jordon RE. Bullous pemphigoid, cicatricial pemphigoid, and chronic bullous dermatosis of childhood. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill Inc, 1987: 580–6
Sison-Fonacier L, Bystryn JC. Regional variations in antigenic properties of skin: a possible cause for disease-specific distribution of skin lesions. J Exp Med 1986; 164: 2125–30
Downham TF, Chapel TA. Bullous pemphigoid: therapy in patients without diabetes mellitus. Arch Dermatol 1978; 114: 1639–42
Provost TT, Maize JC, Ahmed AR, et al. Unusual subepidermal bullous diseases with immunologic features of bullous pemphigoid. Arch Dermatol 1979; 115: 156–60
Ahmed AR, Newcomer VD. Bullous pemphigoid. In: Ahmed AR, editor. Clinics in Dermatology. Philadelphia: JB Lippincott, 1987: 6–12
Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113: 1043–6
Bingham EA, Burrow D, Sanford JC. Prolonged pruritus and bullous pemphigoid. Clin Exp Dermatol 1984; 9: 564–70
Lever WF. Pemphigus and Pemphigoid. Springfield (IL): Charles C Thomas, Inc., 1965: 259–66
Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987; 16: 907–24
Person JR, Rogers III RS. Bullous and cicatricial pemphigoid: clinical, histopathologic and immunopathologic correlations. Mayo Clin Proc 1977; 52: 54–66
Savin JA. Bullous pemphigoid. In: Ahmed AR, editor. Clinics in dermatology. Philadelphia: JB Lippincott, 1987: 52–9
Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol 2002; 138: 903–8
Joly P, Roujeau J-C, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321–7
Flotte TJ. Pathology of pemphigoid. Clin Dermatol 1987; 5: 71–80
Lever WF, Schaumburg-Lever G. Histopathology of the skin. 6th ed. Philadelphia: JB Lippincott Co, 1983
Mutasim DF, Diaz LA. The relevance of immunohistochemical techniques in the differentiation of subepidermal bullous diseases. Am J Dermatopathol 1991; 13: 77–83
Church R. Pemphigoid treated with corticosteroids. Br J Dermatol 1960; 72: 431–41
Siegel J, Eaglstein WH. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984; 120: 1157–65
Greaves MW, Burton JL, Marks J, et al. Azathiprine in treatment of bullous pemphigoid. BMJ 1971; 1: 144–5
Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a 4 year follow-up. Br J Dermatol 1974; 91: 103–9
Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972; 106: 657–61
Thivolet J, Barthelemy H, Rigot-Muller G, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; I: 334–5
Ahmed AR, Moy R. Azathioprine. Int J Dermatol 1981; 20: 461–9
Ahmed AR, Hombal SM. Cyclophosphamide review of relevant pharmacology and clinical use. J Am Acad Dermatol 1984; 6: 1115–26
Person JR, Rogers III RS. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol 1977; 113: 610–5
Goldberg NS, Robinson JK, Roenigk Jr HH, et al. Plasmapheresis therapy for bullous pemphigoid. Arch Dermatol 1985; 121: 1484–5
Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984; II: 486–9
Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49–53
Engineer L, Ahmed AR. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2001; 44: 83–8
Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825–35
Thomas I, Khorenian S, Arbesteld DM. Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993; 28: 74–7
Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753–8
Milligan A, Hutchinson P. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990; 22: 769–801
Khumalo NP, Murrell DF, Wojnarowska F, et al. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002; 138: 385–9
Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214–21
Jacoby Jr WD, Bartholome CW, Ramchand SC, et al. Cicatricial pemphigoid (Brunsting-Perry type) case report and immunofluorescence findings. Arch Dermatol 1978; 114: 779–81
Michel B, Bean SF, Chorzelski T, et al. Cicatricial pemphigoid of Brunsting-Perry. Immunofluorescent studies. Arch Dermatol 1977; 113: 1403–5
Brunsting LA, Perry HO. Benign pemphigoid: a report of seven cases with chronic, scarring, herpetiform plaques about the head and neck. Arch Dermatol 1957; 75: 489–501
Fine J-D. Cicatricial pemphigoid. In: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. New York: Raven Press, 1990: 83–92
Fine J-D. Cicatricial and localized pemphigoid. In: Jordon RE, editor. Immunologic diseases of the skin. Norwalk (CT): Appleton and Lange, 1991: 303–13
Laskaris G, Sklavounou A, Angelopoulos A. Direct immunofluorescence in oral lichen planus. Oral Surg 1982; 53: 483–7
Foster ME, Nally FF. Benign mucous membrane pemphigoid (cicatricial mucosal pemphigoid): a reconsideration. Oral Surg Oral Med Oral Pathol 1977; 44: 697–705
Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 1984; 110: 307–14
Frith PA, Venning VA, Wojnarowska F, et al. Conjunctival involvement in cicatricial and bullous pemphigoid: a clinical and immunopathological study. Br J Ophthalmol 1989; 73: 52–6
Venning VA, Frith PA, Bron AJ, et al. Mucosal involvement in bullous and cicatricial pemphigoid: a clinical and immunopathological study. Br J Dermatol 1988; 118: 7–15
Behlen CH, Mackey DM. Benign mucous membrane pemphigus with a generalized eruption. Arch Dermatol 1965; 92: 566–7
Ackerman AB. Histologic diagnosis of inflammatory skin diseases. Philadelphia: Lea and Febiger 1978
Lever WF, Schaumburg-Lever G. Non-infectious vesicular and bullous diseases. In: Lever WF, Schaumburg-Lever G, editors. Histopathology of the skin. 7th ed. Philadelphia: JB Lippincott Co, 1990: 103–51
Brauner GJ, Jimbow K. Benign mucous membrane pemphigoida unusual case with electron microscopic findings. Arch Dermatol 1972; 106: 535–40
Fine J-D, Neises GR, Katz SI. Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol 1984; 82: 39–43
Bean SF, Waisman M, Michel B, et al. Cicatricial pemphigoid: immunofluorescent studies. Arch Dermatol 1972; 106: 195–9
Fleming MG, Valenzuela R, Bergfeld WF, et al. Mucous gland basement membrane immunofluorescence in cicatricial pemphigoid. Arch Dermatol 1988; 124: 1407–10
Anhalt GJ, Morrison LH. Bullous and cicatricial pemphigoid. Autoimmunity 1991; 4: 17–35
Jabs DA, Anhalt GJ. Cicatricial pemphigoid. In: Provost TT, Farmer ER, editors. Current therapy in dermatology 2. Philadelphia: BC Decker, 1988: 56
Rogers III RS, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6: 215–23
Rogers III RS, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7: 201–5
Fern AI, Jay JL, Young H, et al. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992; 76: 332–5
Elder MJ, Leonard J, Dart JK. Sulphapyridine: a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 549–52
Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23: 254–7
Dragan L, Eng AM, Lam S, et al. Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid. Cutis 1999; 63: 181–3
Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol 1995; 132: 784–9
Brody HJ, Pirozzi DJ. Benign mucous membrane pemphigoid: response to therapy with cyclophosphamide. Arch Dermatol 1977; 113: 1598–9
Dave VK, Vickers CFH. Azathioprine in the treatment of mucocutaneous pemphigoid. Br J Dermatol 1974; 90: 183–6
Kirtschig G, Murreil D, Wojnarowska F, et al. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita. Arch Dermatol 2002; 138: 380–4
Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Ophthalmology 1999; 106: 2136–43
Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch Dermatol 2001; 137: 1181–9
Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy: long-term follow-up: influence of treatment on antibody titres to human α6 integrin. Clin Exp Immunol 2002; 129: 533–40
Sami N, Bhol KC, Ahmed AR. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol Immunopathol 2002; 102: 59–67
Letko E, Bhol K, Foster CS, et al. Influence of intravenous immunogloublin therapy on serum levels of anti-β4 antibodies in ocular cicatricial pemphigoid. Curr Eye Res 2000; 21: 646–54
Yaoita H, Briggaman RA, Lawley TJ, et al. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol 1981; 76: 288–92
Nieboer C, Boorsma DM, Woerdeman MJ, et al. Epidermolysis bullosa acquisita: immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol 1980; 102: 383–92
Woodley DT, Briggaman RA, O’Keefe EJ, et al. Identification of the skin basement membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007–13
Sakai LY, Keene DR, Morris NP, et al. Type VII collagen is a major structural component of anchoring fibrils. J Cell Biol 1986; 103: 1577–86
Briggaman RA, Wheeler Jr CE. The epidermal-dermal junction. J Invest Dermatol 1975; 65: 71–84
Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001; 44: 818–28
Cunningham BB, Kirchmann TTT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34: 781–4
Megahed M, Scharffetter-Kochanek K. Epidermolysis bullosa acquisita: successful treatment with colchicine. Arch Dermatol Res 1994; 286: 35–40
Kofler H, Wambacher-Gasser B, Topar G, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol 1996; 34: 331–5
Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photo-chemotherapy. Br J Dermatol 1997; 136: 415–20
Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40: 741–8
Ansel J, Petrozzi JW, Kumar V. Possible drug-induced pemphigus-like antibodies with clinical manifestation of erythema multiforme. Arch Dermatol 1983; 119: 1006–9
Coulson IH, Cook MG, Bruton J, et al. Atypical pemphigus vulgaris associated with angio-follicular lymph node hyperplasia (Castleman’s disease). Clin Exp Dermatol 1986; 11: 656–63
Gili A, Ngan BY, Lester R. Castleman’s disease associated with pemphigus vulgaris. J Am Acad Dermatol 1992; 25: 955–9
Tagami S, Imamura S, Noguchi S, et al. Coexistence of peculiar pemphigus, myasthenia gravis and malignant thymoma. Dermatologica 1976; 152: 181–90
Anhalt GJ, Kim S, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–35
Fullerton SH, Woodley DT, Smoller BR, et al. Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation. JAMA 1992; 267: 1500–2
Lam S, Stone MS, Goeken JA, et al. Paraneoplastic pemphigus, cicatricial conjunctivitis, and acanthosis nigricans with pachydermatoglyphy in a patient with bronchogenic squamous cell carcinoma. Ophthalmology 1992 Jan; 99(1): 108–13
Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol 1997; 12: 77–97
Camisa C, Helm TN, Valenzuela R, et al. Paraneoplastic pemphigus: three new cases [abstract]. J Invest Dermatol 1992; 98: 590
Dega H, LaPorte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin’s disease. Br J Dermatol 1998; 138: 196–7
Krunic ALJ, Kokai D, Bacetic B, et al. Retroperitoneal round-cell liposarcoma associated with paraneoplastic pemphigus presenting as lichen planus pemphigoides-like eruption. Int J Dermatol 1997; 36: 526–9
Robinson ND, Hashimoto T, Amagai M, et al. The new pemphigus variants. J Am Acad Dermatol 1999; 40: 649–71
Hertzberg MS, Schifter M, Sullivan J, et al. Paraneoplastic pemphigus in two patients with B cell non-Hodgkin’s lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63: 105–6
Korman NJ. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 2000; 18: 127–37
Williams JV, Marks Jr JG, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506–8
Acknowledgements
No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mutasim, D.F. Autoimmune Bullous Dermatoses in the Elderly. Drugs Aging 20, 663–681 (2003). https://doi.org/10.2165/00002512-200320090-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200320090-00004